Search PubMed⌕ Search

Biomedical subjects

K Ota

Publications and source records attributed to K Ota.

At least 469 records · Page 26Linked to original sources
PubMed1989

[The correlation of serum parathyroid hormones among patients with dementia of vascular type, hemodialysis, and bone-joint disorders].

PTH levels were analysed in sera of patients receiving maintenance hemodialysis, with the vascular type of dementia and orthopedic patients with bone-joint disorders, using PTH assay kits. There were significant interrelationship among all kinds of PTH levels in the hemodialysis patients, but not in patients with the vascular type of dementia and the bone-joint disorders. Renal functions might be responsible for fragmentation of PTH in blood stream. These results suggested that the measurement of PTH levels is needed to examine various kinds of amino-sequence of PTH levels in keeping normal function of kidney.

Aged↗
PubMed1989

[Clinical features and treatment of lower intestinal hemorrhage].

We have experienced 471 patients with anal bleeding during the past seven years. The Results are as follows: 1. As for the types of disease, incidence of hemorrhoid, colorectal cancer and ulcerative colitis (UC) was high, while that of small intestinal problems was low. 2. In the cases of remarkable bleeding from the lower intestinal tract, massive or acute progressive bleeding was less frequent than expected. 3. Inflammatory diseases were the main causes of massive bleeding. Bleeding by UC was the major indication for urgent operation. In the cases with acute massive hemorrhage, basic complications were often found and the possibility of the diseases of small intestine and blood vessel disorders also should be considered. 4. At the examination of bleeding patients, it is efficient to explore the lower colon and rectum first by colonoscopy or sigmoidoscopy, for most of the bleeding lesions are found in these portions. 5. As for surgical treatment, most of colorectal cancer patients with hemorrhage are able to be operated with wait- and -see management. For UC patients, complete cure operation is possible even if they have high-dose steroid medication.

Adult↗
PubMed1989

Recent trends in the treatment and prognosis of adult leukemia with characteristics of patients in Japan: transition during the fifteen years from 1971 to 1985.

Patients with acute (2,569) and chronic (957) leukemia diagnosed at 19 institutes took part in the study on the "Multidisciplinary Treatment of Leukemia" between 1971 and 1985 and were investigated retrospectively. By dividing the 15 years into three five-year periods, we were able to compare patient ratios in the different periods. The proportions of acute to chronic leukemia cases showed no obvious change; however, the proportions of cases diagnosed as acute lymphocytic leukemia in acute leukemia showed a significant increase. The main chemotherapeutic drugs used during the three time periods were cytarabine or its analogues, the anthracyclines, 6-mercaputopurine and prednisolone, against acute myelogenous leukemia, and the vinca alkaloids, prednisolone and the anthracyclines against acute lymphocytic leukemia. The rate of complete remission from acute myelogenous leukemia made marked progress, from 45.1% during 1971-1975 to 62.3% during 1981-1985, but that of acute lymphocytic leukemia showed no significant progress, being 65% during 1971-1975 and 69.7% during 1981-1985. The durations of remission, however, and the survival times for patients with acute lymphocytic leukemia, as well as for those with acute myelogenous leukemia, became significantly longer over the three periods. Median survival times from chronic myelocytic leukemia were 37-40 mo in all three periods, showing no progress. There was a better prognosis in cases of chronic myelocytic leukemia with, than without, Philadelphia chromosome. Except for a low incidence of chronic lymphocytic leukemia in Japan, adult leukemia patients' characteristics and prognoses seem to be almost the same in Japan as in the U.S.A. and Europe.

Adolescent↗
PubMed1989

Stannous fluoride and its effects on oral microbial adhesive properties in vitro.

The effect of sodium and stannous fluoride compounds on the coherence of Streptococcus mutans was examined. Both commercial and reagent grade preparations were tested on S. mutans, strain 6715. Test fluoride aliquots at various concentrations were added to sucrose suspensions of S. mutans at a starting microbial suspensions equivalent to 25% transmission as read in a spectrophotometer. Test samples were rotated at 35 degrees, 80 rpm in an incubated orbital shaker. Analysis at 560 nm at various time periods, was performed to determine increases in %T as a function of aggregate formation. SnF2 preparations routinely inhibited coherence at concentrations as low as .001%, whereas NaF showed no effects on microbial cell-to-cell coherence.

Bacterial Adhesion↗
PubMed1989

[Calcium regulating hormone in the pathological changes of bone in rheumatoid arthritis].

To further elucidate the pathogenesis of calcium regulating hormones and bone Gla-protein (BGP) on the deteriorated bone changes in rheumatoid arthritis (RA), the degree of the appendicular bone atrophy, using microdensitometry method in patients with RA, and the concentrations of midchain mainly recognized parathyroid hormone (p-PTH1-84, intact parathyroid hormone (in-PTH1-84) and BGP in sera of patients with RA were measured. With concomitant progression in X-ray stage in RA, the levels of p-PTH1-84, in-PTH1-84, BGP, 25 (OH) D, and 24, 25 (OH)2D were significantly increased in sera of RA patients. The levels of 1,25 (OH)2D were not shown significant differences among RA patients classified by bone stage. These results might be concluded that the pathogenesis of the deteriorated bone change in RA seemed to be implicated in hyper-turnover bone presumably caused by the actions of parathyroid hormone and abnormal vitamin D metabolism.

1-Carboxyglutamic Acid↗
PubMed1989

[Phase I study and early phase II of SM-108 (4-carbamoylimidazolium-5-olate) in lung cancer. SM-108 Study Group].

Phase I study with a new oral purine antagonist, SM-108, was conducted in a total of 73 cases in a 5-day consecutive schedule with the dosage ranging from 20-2,500 mg/m2 at II institutes. The incidences of subjective and objective side effects were 20.5% (15/73) and 31.5% (23/73), respectively, however the correlation between these effects and their dosages was unclear. MTD and DLF values were not determined. SM-108 levels in serum reached maximum in 2-4 hours after oral administration of SM-108, and exhibited a dose-response relationship up to the dosage of 2,000 mg/m2/day. Forty to 60% of the administered drug was excreted into urine in 24 hrs; thus, the main excretory pathway was considered to be renal. An early phase II study was undertaken in patients with lung cancer in 5 cancer centers and university hospitals. Each patient had received 400 mg/m2/day (in two divided doses) or 600 mg/m2/day (in three divided doses) for more than 2 weeks. Only one case (adenocarcinoma) showed a minor response out of 27 cases but not reached partial response according to our criteria. In the 400 mg/m2/day group and the 600 m/m2/day group the incidences of subjective side effects (mainly GI tract disturbance) were 33.3% (4/12) and 40.0% (6/15), while objective side effects (hematological changes) were 16.7% (2/12) and 26.7% (4/15) respectively. In conclusion, we could not determine the dose limiting factor and maximum tolerated dose from our phase I clinical study and early phase II study for lung cancer.

Adenocarcinoma↗